Reneo Pharmaceuticals, Inc. (RPHM)

NASDAQ: RPHM · IEX Real-Time Price · USD

1.480

+0.010 (0.68%)

At close: Jul 19, 2024, 4:30 PM

1.430

-0.050 (-3.38%)

Pre-market: Jul 22, 2024, 6:10 AM EDT

Reneo Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	25.93	26.44	16.14	11.65	3.61	2.38
Research & Development	50.57	56.61	37.71	28.17	15.94	13.1
Operating Expenses	76.5	83.05	53.85	39.82	19.55	15.47
Operating Income	-76.5	-83.05	-53.85	-39.82	-19.55	-15.47
Other Expense / Income	-5.79	-5.67	-1.89	-0.05	-0.09	-3.04
Pretax Income	-70.71	-77.39	-51.96	-39.77	-19.47	-12.44
Net Income	-70.71	-77.39	-51.96	-39.77	-19.47	-12.44
Shares Outstanding (Basic)	33	31	24	18	2	2
Shares Outstanding (Diluted)	33	31	24	18	2	2
Shares Change	33.49%	25.23%	35.01%	794.56%	4.11%	-
EPS (Basic)	-2.18	-2.52	-2.12	-2.19	-9.60	-6.38
EPS (Diluted)	-2.18	-2.52	-2.12	-2.19	-9.60	-6.38
Free Cash Flow	-75.7	-63.9	-47.71	-38.18	-18.56	-12.52
Free Cash Flow Per Share	-2.27	-2.08	-1.95	-2.10	-9.15	-6.42
EBITDA	-70.26	-76.86	-51.43	-39.72	-19.43	-12.4
Depreciation & Amortization	0.45	0.53	0.53	0.05	0.04	0.03
EBIT	-70.71	-77.39	-51.96	-39.77	-19.47	-12.44

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).